FDA warned 30 telehealth companies early in 2026 and 25 more in June over compounded GLP-1 marketing, and a STAT analysis tied at least 30% of warned firms to a handful of white-label platforms. Every Bask brand builds its pages in Bask's builder, so Bask can stop the risky sentence at the moment it is typed.
First action
List every phrase quoted in the March and June 2026 warning letters and search live Bask storefronts for them.
How to measure it
Flagged phrases left live after a warning
- Now
- –
- Target
- under 5% of flags
- By
- 6 weeks after launch
Steps
Collect the phrases
Every claim type quoted in the 2026 letters, grouped by risk.
Product Marketing Manager 1 day
Scan live storefronts
Find how many Bask brands use them today, privately.
Senior Back-End Software Engineer 2 days
Build the check
Inline highlight with a one-line reason and a link to guidance.
Senior Back-End Software Engineer 1 week
Write the guidance
Plain safer wording for each flagged claim.
Product Marketing Manager 2 days
Compliance review
Check every claim about drugs, pharmacies and outcomes against FDA misbranding rules and the HIPAA marketing rules before it ships.
Head of Product 1 day
Launch it
A launch page, release note and a note to every brand owner.
Product Marketing Manager 1 day
Run this outreach. The sequence sent for you: addresses found and verified, replies routed to your CRM. Usually live within days.
Book a working sessionWhy it works
Add a check to the website and questionnaire builder that highlights phrases cited in the 2026 letters ("FDA-approved pharmacy", "clinically studied", "same as Ozempic", hiding the compounding pharmacy), explains why in one line, links Bask's own FDA warning letter post, and logs that the brand saw it. Launch it as "the platform whose brands do not get letters".
The first product marketer is asked to turn features into positioning a customer repeats, and this is the one competitors cannot easily claim after the STAT finding. It also protects Bask itself, because a warned brand reflects on its platform.
Ready to use
EmailBrand owner note
Subject: We now flag the claims FDA has been warning telehealth brands about
Hi {first name},
FDA sent warning letters to 55 telehealth companies this year over how they describe compounded medications. Starting today, the Bask builder highlights the phrases those letters cite, like "FDA-approved pharmacy" or "clinically studied", and suggests safer wording before you publish.
Your store has {n} phrases worth a look: {link}
This is guidance, not legal advice; your counsel has the final word.
The Bask teamRisks and how to handle them
Bask appears to give legal advice
Label the check as guidance and point brands to their own counsel.
Brands resent friction
Warn, never block, and keep the reason to one line.
Evidence
- Search resultsFDA sent warning letters to 30 telehealth companies in early 2026 over compounded GLP-1 marketing (presenting compounded drugs as if they matched approved ones, hiding where they came from) and 25 more in June, citing claims such as "clinically studied" ingredients and an "FDA-approved pharmacy".Source
- Competitor researchWhite-label competitors: MD Integrations (physician network with API and Shopify plugins, all 50 states), OpenLoop (provider staffing, licensing and revenue cycle for digital health), Beluga Health (physician-led white-label virtual care). A STAT analysis found at least 30% of 70+ FDA-warned telehealth firms were publicly affiliated with Beluga, OpenLoop, MD Integrations or Telegra.Source
- Your websiteBlog: compliance-led posts such as "Reading an FDA Warning Letter as a Telehealth Brand", "Why Telehealth Patients Dispute Real Charges", the HIPAA minimum necessary rule, the 60-day breach notification clock and "Anti-Kickback Statute Risks in Common Telehealth Deals", plus marketing and paid-media tags.Source
- HiringProduct Marketing Manager (the first): "We have never had a dedicated product marketer"; reports to the Head of Product; two audiences, "entrepreneurs launching a DTC telehealth brand and healthtech companies building on our platform and API"; owns positioning, launches, competitor comparisons, ROI and pricing narratives, website copy, case studies and "a repeatable content motion (SEO, case studies, launch pages)"; turns "our best wins into public proof".Source
- Your websiteHomepage: "Bask provides a full service software that allows you to build any digital health experience. Built for entrepreneurs, doctors, and developers"; a "Private Beta" label; white-label telehealth, a drag-and-drop questionnaire builder "as simple as setting up a Shopify store", patient, doctor and admin portals, and a pharmacy network for "commercial, compounded and speciality medications nationwide" in all 50 states.Source